



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

GLI1-IN-1

Cat. No.:	HY-161459
CAS No.:	2923907-92-8
Molecular Formula:	C ₄₂ H ₆₀ N ₂ O ₉
Molecular Weight:	736.93
Target:	Apoptosis; Hedgehog; Gli
Pathway:	Apoptosis; Stem Cell/Wnt
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	GLI1-IN-1 (CBC-1) is a GLI-1 inhibitor with excellent water solubility and anticancer activity. GLI1-IN-1 can induce apoptosis and suppress the growth of colorectal cancer by inhibiting the Hedgehog(HH) (IC ₅₀ =1.3 μM) pathway ^[1] .																
IC₅₀ & Target	IC ₅₀ : 1.3 μM (Hedgehog) ^[1] .																
In Vitro	<p>GLI1-IN-1 (CBC-1) (5-40 μM; 24-48 h) exhibits anticancer activity by inhibiting cell proliferation through suppressing the mRNA and protein expression of the HH pathway in HT-29, SW-480, and HCT-116 cells, with IC₅₀ values of 7.13, 15.31, and 3.33 μM, respectively. GLI1-IN-1 (5-40 μM; 24 h) can also induce apoptosis in HT-29 cells^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Apoptosis Analysis^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>HT-29</td> </tr> <tr> <td>Concentration:</td> <td>5, 10, 20, 40 μM;</td> </tr> <tr> <td>Incubation Time:</td> <td>24 h</td> </tr> <tr> <td>Result:</td> <td>Increased the number of apoptotic cells in a concentration-dependent manner.</td> </tr> </table> <p>RT-PCR^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>HT-29</td> </tr> <tr> <td>Concentration:</td> <td>5, 10, 20, 40 μM;</td> </tr> <tr> <td>Incubation Time:</td> <td>24 h, 48 h</td> </tr> <tr> <td>Result:</td> <td>Decreased the mRNA expression of SHH, SMO, GLI1, and PTCH in a concentration- and time-dependent manner. Significantly reduced the mRNA expression levels of the apoptosis-related factor BCL-2 and increased the levels of the apoptosis-promoting factor BAX in a dose-dependent manner.</td> </tr> </table> <p>Western Blot Analysis^[1]</p>	Cell Line:	HT-29	Concentration:	5, 10, 20, 40 μM;	Incubation Time:	24 h	Result:	Increased the number of apoptotic cells in a concentration-dependent manner.	Cell Line:	HT-29	Concentration:	5, 10, 20, 40 μM;	Incubation Time:	24 h, 48 h	Result:	Decreased the mRNA expression of SHH, SMO, GLI1, and PTCH in a concentration- and time-dependent manner. Significantly reduced the mRNA expression levels of the apoptosis-related factor BCL-2 and increased the levels of the apoptosis-promoting factor BAX in a dose-dependent manner.
Cell Line:	HT-29																
Concentration:	5, 10, 20, 40 μM;																
Incubation Time:	24 h																
Result:	Increased the number of apoptotic cells in a concentration-dependent manner.																
Cell Line:	HT-29																
Concentration:	5, 10, 20, 40 μM;																
Incubation Time:	24 h, 48 h																
Result:	Decreased the mRNA expression of SHH, SMO, GLI1, and PTCH in a concentration- and time-dependent manner. Significantly reduced the mRNA expression levels of the apoptosis-related factor BCL-2 and increased the levels of the apoptosis-promoting factor BAX in a dose-dependent manner.																

	Cell Line:	HT-29
	Concentration:	5, 10, 20, 40 μ M;
	Incubation Time:	24 h
	Result:	Decreased the protein expression of SHH, SMO and GLI1 in a concentration-dependent manner.
In Vivo	<p>CBC-1 (50 mg/kg; i.p.; once daily for 16 days) can effectively inhibit tumor growth in xenograft models, with a remarkable tumor inhibition rate of 68% in BALB/c/nu/nu nude mice^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>	
	Animal Model:	Tumour xenograft BALB/c/nu/nu nude mice model ^[1] .
	Dosage:	50 mg/kg
	Administration:	Intraperitoneal injection (i.p.); Once daily for 16 days
	Result:	Significantly reduced the size and weight of HT29 tumor xenografts. Decreased the protein expression of GLI -1.

REFERENCES

[1]. Chen J, et al. CBC-1 as a Cynanbungeigenin C derivative inhibits the growth of colorectal cancer through targeting Hedgehog pathway component GLI 1. Steroids. Published online April 11, 2024.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA